Clinical trials in Barcelona – page 27

3 182 clinical trials in Barcelona, Spain across 23 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Barcelona at a glance

3 182

clinical trials

Research sites23

Quick filters

3 182 trials in Barcelona

Open in trial search

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

A study to evaluate the effect of zigakibart in adults with IgA nephropathy

Recruiting

InvestigationalNo placebo

A study to evaluate the effect of zigakibart in adults with IgA nephropathy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Zigakibart
Sponsor:Novartis Pharma AG

Contact Research Centre

Ischaemic stroke

Recruiting

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Pyelonephritis

Recruiting

Comparing the effectiveness of 7 days versus 14 days of ciprofloxacin or ceftriaxone for treating kidney infection in kidney transplant recipients

Registered drugNo placebo

Comparing the effectiveness of 7 days versus 14 days of ciprofloxacin or ceftriaxone for treating kidney infection in kidney transplant recipients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ceftriaxone
Sponsor:Bellvitge University Hospital

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barcelona

What the registry says about research in the country

01 Neurodegenerative Research

Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.

Cerebral tau aggregates assessment
Amyloid deposition tracking
Progressive supranuclear palsy research

Advanced neuroimaging studies using PET tracers to understand disease mechanisms.

02 Infectious Disease Prevention

Comprehensive vaccine trials targeting various infections including respiratory syncytial virus, Cytomegalovirus, and Herpes Zoster.

RSV vaccine development for older adults
CMV prevention studies
COVID-19 booster research

Focus on developing effective immunization strategies for vulnerable populations.

03 Metabolic and Chronic Conditions

Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.

Diabetes management therapies
Cancer immunotherapy trials
UTI vaccine development

Innovative approaches to chronic disease management and prevention.

Back to Spain All countries